Xencor Inc. (XNCR) 10.34 $XNCR
Nasdaq stocks posting largest percentage increases
AP - Wed Apr 16, 12:31PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 Clinical Trial of a Biologic Candidate using XmAb® Antibody Engineering Intellectual Property
PR Newswire - Thu Apr 10, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the company has received a milestone payment from Merck, through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb® antibody engineering intellectual property.
Xencor Showcases Bispecific Antibody Programs at Annual Summit on Practical and Emerging Trends in Multiple Myeloma
PR Newswire - Fri Mar 28, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today presented an overview of its bispecific antibody programs at the Annual Summit on Practical and Emerging Trends in Multiple Myeloma being held in Whistler, British Columbia, Canada. The discussion featured Xencor's bispecific approach for recruiting cytotoxic T cells against tumors using novel XmAb heterodimeric Fc domains, and highlighted its bispecific program against CD38, a target antigen on multiple myeloma cells.
Xencor to Present at 21st Annual BioCentury Future Leaders in the Biotech Industry Conference
PR Newswire - Mon Mar 24, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., Chief Executive Officer, will present at the 21st Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, March 28, 2014 at 9:30 a.m. EDT at the Millennium Broadway Hotel & Conference Center in New York, NY.
Xencor Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Wed Mar 19, 3:01PM CDT
Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided a review of business highlights.
Xencor, Inc. to Host Fourth Quarter and Full Year 2013 Financial Results Webcast and Conference Call
PR Newswire - Thu Mar 13, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor management will host a webcast and conference call the same day at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial results and provide a corporate update.
Global Proteomics Market 2012-2016: One of the Main Drivers in This Market Is the Increasing Demand for Personalized Medicines
M2 - Fri Feb 28, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/dn2hwq/global_proteomics) has announced the addition of the "Global Proteomics Market 2012-2016" report to their offering. The analysts forecast the Global Proteomics market to grow at a CAGR of 14.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicines. The Global Proteomics market has also been witnessing a shift from genomics to proteomics. However, the intense competition among vendors could pose a challenge to the growth of this market. The key vendors dominating this space are Thermo Fischer Scientific Inc., Agilent Technologies Inc., Life Technologies Corp., and Danaher Corp. The other vendors mentioned in the report are Sigma-Aldrich Corp., Roche Diagnostics Corp., Betcon Dickinson and Co., Affymetrix Inc., Shimadzu Corp., Bio Rad Laboratories Inc., Illumina Inc., Abbott Laboratories, GE Healthcare Ltd., Perkin Elmer Inc., Xencor Inc., Cellzome AG, Waters Corp., Dionex Corp., and Bruker Daltonics Inc. Commenting on the report, an analyst from the Healthcare team said: ''One of the recent trends being witnessed in the Global Proteomics market is the growing popularity of proteomic analysis as compared to genomic analysis. Both genomics and proteomics find application in drug discovery, disease diagnosis, and drug development. Genomics is the study of the genes or DNA of an organism. Proteomics, which was introduced after genomics, has become more popular because it offers more benefits than genomics. For instance, proteomic analysis is faster and more effective in terms of data analysis than genomic analysis. Thus, there is a considerable shift from genomics to proteomics for disease diagnosis and drug development. This trend augers well for the growth of the Global Proteomics market during the forecast period.'' For more information visit http://www.researchandmarkets.com/research/dn...proteomics About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
4 Biotech Stocks Under $10 to Watch
at The Street - Tue Feb 18, 1:30PM CST
Keep these under-$10 biotech stocks trading on unusual volume on your radar.
Xencor to Present at 2014 Leerink Global Healthcare Conference
PR Newswire - Thu Feb 06, 3:01PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., Chief Executive Officer, will present at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 2:15 p.m. EST at the Waldorf Astoria Hotel in New York, NY.
2013 Report on the International Protein Engineering Market - Includes Forecast to 2017
M2 - Fri Dec 20, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8lvw7/protein) has announced the addition of the "2013 Report on the International Protein Engineering Market - Includes Forecast to 2017" report to their offering. There are more than 200 protein-based products currently being marketed; 90% of them are used as therapeutics. In order to improve their clinical potential, second generation recombinants are being developed, each exhibiting improved efficiency and potency depending on their applications. The protein engineering market is driven by the need for drugs with improved efficiency and specificity, technological capabilities, rise of antibody based drugs, and steady growth in the therapeutic market. With growing incidences of cancer, autoimmune disorders, and infectious disease, spurt of new opportunities for growth of the market is expected by the end of this decade. The use of monoclonal antibodies in therapeutics such as oncology, auto immune and inflammatory diseases are expected to increase during the forecast period. Chinas growing interest in research of monoclonal antibodies is expected to increase market share further. The market is likely to face competition from the entry of generics; however, with many therapeutic proteins in the pipeline, the market is expected to grow exponentially. Insulin analogs, which are more efficient than the recombinant insulin, are also a contributing factor for growth of the market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Protein Engineering Technologies - Landscape Analysis 4 Applications 5 Market Landscape Analysis 6 Geographic Analysis 6.1 North America 6.2 Europe 6.3 Asia 6.4 Row 7 Technology And Product Portfolio 8 Competitive Landscape 8.1 Introduction 8.2 Porter'S Five Force Analysis 8.3 Mergers & Acquisitions, 2009 - 2012 8.4 Partnerships & Collaborations, 2012 - 2013 8.5 New Product Launch, 2010 - 2012 9 Analyst Insights And Recommendation 10 Company Profiles Companies Mentioned: - Amgen. - Avidbiotics Corp. - Biogen Idec. - Bristol Myers Squibb Co. - Dna2.0. - Eleven Biotherapeutics - Eli Lilly & Co - Genentech. - Glaxo Smithkline Plc - Johnson & Johnson - Merck & Co.. - Morphosys - Novartis Ag - Pfizer. - Regeneron Pharmaceuticals. - Sanofi - Sigma-Aldrich Corp. - Toolgen. (Korea) - Xencor Inc. For more information visit http://www.researchandmarkets.com/research/h8lvw7/protein
Xencor, Inc. Announces Closing of Initial Public Offering
PR Newswire - Fri Dec 06, 11:20AM CST
Xencor, Inc. (NASDAQ: XNCR) today announced the closing of its initial public offering of 14,639,500 shares of its common stock at an initial public offering price of $5.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,909,500 additional shares of common stock. Xencor's common stock is listed on The NASDAQ Global Market under the trading symbol "XNCR." All of the shares in the offering were offered by Xencor. Xencor estimates net proceeds from the offering to be approximately $72.4 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Xencor trades higher after IPO prices at $70M
AP - Tue Dec 03, 9:32AM CST
NEW YORK (AP) — Shares of Xencor are rising after the biotechnology company's initial public offering raised $70 million, at the low end of its expectations.
MorphoSys Strengthens European Patent Position on anti-CD19 Cancer Program MOR208
GlobeNewswire - Tue Dec 03, 12:36AM CST
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that the European Patent Office has granted a patent covering the Company's cancer compound MOR208. The new patent (EP2383297) covers the antibody's protein and nucleic acid sequences as well as pharmaceutical compositions comprising the same. The new patent has a scheduled expiry date in 2027, not including any potential patent office or regulatory extensions, and is licensed to MorphoSys AG from Xencor, Inc.
Nasdaq stocks posting largest percentage increases
AP - Wed Apr 16, 12:31PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 Clinical Trial of a Biologic Candidate using XmAb® Antibody Engineering Intellectual Property
PR Newswire - Thu Apr 10, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the company has received a milestone payment from Merck, through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb® antibody engineering intellectual property.
Xencor Showcases Bispecific Antibody Programs at Annual Summit on Practical and Emerging Trends in Multiple Myeloma
PR Newswire - Fri Mar 28, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today presented an overview of its bispecific antibody programs at the Annual Summit on Practical and Emerging Trends in Multiple Myeloma being held in Whistler, British Columbia, Canada. The discussion featured Xencor's bispecific approach for recruiting cytotoxic T cells against tumors using novel XmAb heterodimeric Fc domains, and highlighted its bispecific program against CD38, a target antigen on multiple myeloma cells.
Xencor to Present at 21st Annual BioCentury Future Leaders in the Biotech Industry Conference
PR Newswire - Mon Mar 24, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., Chief Executive Officer, will present at the 21st Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, March 28, 2014 at 9:30 a.m. EDT at the Millennium Broadway Hotel & Conference Center in New York, NY.
Xencor Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Wed Mar 19, 3:01PM CDT
Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided a review of business highlights.
Xencor, Inc. to Host Fourth Quarter and Full Year 2013 Financial Results Webcast and Conference Call
PR Newswire - Thu Mar 13, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor management will host a webcast and conference call the same day at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial results and provide a corporate update.
Global Proteomics Market 2012-2016: One of the Main Drivers in This Market Is the Increasing Demand for Personalized Medicines
M2 - Fri Feb 28, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/dn2hwq/global_proteomics) has announced the addition of the "Global Proteomics Market 2012-2016" report to their offering. The analysts forecast the Global Proteomics market to grow at a CAGR of 14.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicines. The Global Proteomics market has also been witnessing a shift from genomics to proteomics. However, the intense competition among vendors could pose a challenge to the growth of this market. The key vendors dominating this space are Thermo Fischer Scientific Inc., Agilent Technologies Inc., Life Technologies Corp., and Danaher Corp. The other vendors mentioned in the report are Sigma-Aldrich Corp., Roche Diagnostics Corp., Betcon Dickinson and Co., Affymetrix Inc., Shimadzu Corp., Bio Rad Laboratories Inc., Illumina Inc., Abbott Laboratories, GE Healthcare Ltd., Perkin Elmer Inc., Xencor Inc., Cellzome AG, Waters Corp., Dionex Corp., and Bruker Daltonics Inc. Commenting on the report, an analyst from the Healthcare team said: ''One of the recent trends being witnessed in the Global Proteomics market is the growing popularity of proteomic analysis as compared to genomic analysis. Both genomics and proteomics find application in drug discovery, disease diagnosis, and drug development. Genomics is the study of the genes or DNA of an organism. Proteomics, which was introduced after genomics, has become more popular because it offers more benefits than genomics. For instance, proteomic analysis is faster and more effective in terms of data analysis than genomic analysis. Thus, there is a considerable shift from genomics to proteomics for disease diagnosis and drug development. This trend augers well for the growth of the Global Proteomics market during the forecast period.'' For more information visit http://www.researchandmarkets.com/research/dn...proteomics About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
4 Biotech Stocks Under $10 to Watch
at The Street - Tue Feb 18, 1:30PM CST
Keep these under-$10 biotech stocks trading on unusual volume on your radar.
Xencor to Present at 2014 Leerink Global Healthcare Conference
PR Newswire - Thu Feb 06, 3:01PM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., Chief Executive Officer, will present at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 2:15 p.m. EST at the Waldorf Astoria Hotel in New York, NY.
2013 Report on the International Protein Engineering Market - Includes Forecast to 2017
M2 - Fri Dec 20, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8lvw7/protein) has announced the addition of the "2013 Report on the International Protein Engineering Market - Includes Forecast to 2017" report to their offering. There are more than 200 protein-based products currently being marketed; 90% of them are used as therapeutics. In order to improve their clinical potential, second generation recombinants are being developed, each exhibiting improved efficiency and potency depending on their applications. The protein engineering market is driven by the need for drugs with improved efficiency and specificity, technological capabilities, rise of antibody based drugs, and steady growth in the therapeutic market. With growing incidences of cancer, autoimmune disorders, and infectious disease, spurt of new opportunities for growth of the market is expected by the end of this decade. The use of monoclonal antibodies in therapeutics such as oncology, auto immune and inflammatory diseases are expected to increase during the forecast period. Chinas growing interest in research of monoclonal antibodies is expected to increase market share further. The market is likely to face competition from the entry of generics; however, with many therapeutic proteins in the pipeline, the market is expected to grow exponentially. Insulin analogs, which are more efficient than the recombinant insulin, are also a contributing factor for growth of the market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Protein Engineering Technologies - Landscape Analysis 4 Applications 5 Market Landscape Analysis 6 Geographic Analysis 6.1 North America 6.2 Europe 6.3 Asia 6.4 Row 7 Technology And Product Portfolio 8 Competitive Landscape 8.1 Introduction 8.2 Porter'S Five Force Analysis 8.3 Mergers & Acquisitions, 2009 - 2012 8.4 Partnerships & Collaborations, 2012 - 2013 8.5 New Product Launch, 2010 - 2012 9 Analyst Insights And Recommendation 10 Company Profiles Companies Mentioned: - Amgen. - Avidbiotics Corp. - Biogen Idec. - Bristol Myers Squibb Co. - Dna2.0. - Eleven Biotherapeutics - Eli Lilly & Co - Genentech. - Glaxo Smithkline Plc - Johnson & Johnson - Merck & Co.. - Morphosys - Novartis Ag - Pfizer. - Regeneron Pharmaceuticals. - Sanofi - Sigma-Aldrich Corp. - Toolgen. (Korea) - Xencor Inc. For more information visit http://www.researchandmarkets.com/research/h8lvw7/protein
Xencor, Inc. Announces Closing of Initial Public Offering
PR Newswire - Fri Dec 06, 11:20AM CST
Xencor, Inc. (NASDAQ: XNCR) today announced the closing of its initial public offering of 14,639,500 shares of its common stock at an initial public offering price of $5.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,909,500 additional shares of common stock. Xencor's common stock is listed on The NASDAQ Global Market under the trading symbol "XNCR." All of the shares in the offering were offered by Xencor. Xencor estimates net proceeds from the offering to be approximately $72.4 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Xencor trades higher after IPO prices at $70M
AP - Tue Dec 03, 9:32AM CST
NEW YORK (AP) — Shares of Xencor are rising after the biotechnology company's initial public offering raised $70 million, at the low end of its expectations.
MorphoSys Strengthens European Patent Position on anti-CD19 Cancer Program MOR208
GlobeNewswire - Tue Dec 03, 12:36AM CST
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that the European Patent Office has granted a patent covering the Company's cancer compound MOR208. The new patent (EP2383297) covers the antibody's protein and nucleic acid sequences as well as pharmaceutical compositions comprising the same. The new patent has a scheduled expiry date in 2027, not including any potential patent office or regulatory extensions, and is licensed to MorphoSys AG from Xencor, Inc.
